Role of tru-cut bio psy in the management of myometrial lesions

Czech version

Authors: A. Richtárová; K. Hlinecká; Z. Lisá; V. Lukavec; V. Vaisová; M. Mára
Authors‘ workplace: Klinika gynekologie, porodnictví a neonatologie 1. LF UK a VFN v Praze
Published in: Ceska Gynekol 2025; 90(4): 328-332
Category:
doi: https://doi.org/10.48095/cccg2025328

Overview

The aim of this article was to summarize current knowledge regarding ultrasound-guided tru-cut biopsy, with a focus on its applicability in preoperative diagnosis of myometrial lesions. Tru-cut biopsy is used in gynecologic oncology for the management of pelvic and abdominal tumors; however, its application in the diagnostic algorithm for uterine tumors has been validated by only a limited number of studies. Nevertheless, this literature review highlights that tru-cut biopsy of uterine smooth muscle lesions demonstrates high sample adequacy for histological examination, diagnostic accuracy, and a low complication rate. Leiomyomas are among the most common benign uterine tumors, whereas uterine sarcomas are rare and aggressive malignancies. Symptoms of these conditions do not differ significantly. Their differentiation relies on imaging methods such as ultrasonography and magnetic resonance imaging. However, distinguishing between benign and malignant tumors remains challenging, as criteria for differentiating benign and malignant lesions using these imaging methods have not yet been sufficiently validated. Incorporating tru-cut biopsy into the standard diagnostic algorithm for uterine tumors could provide valuable insights into the oncological nature of atypical tumors on ultrasonography or magnetic resonance imaging, leading to optimized and personalized treatment strategies for each patient.

Keywords:

Biopsy – differential diagnosis – Leiomyoma – sarcoma – uterine neoplasms

Sources

1. Stewart EA, Cookson CL, Gandolfo RA et al. Epidemiology of uterine fibroids: a systematic review. BJOG 2017; 124 (10): 1501–1512. doi: 10.1111/1471-0528.14640.

2. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet 2020; 149 (1): 3–9. doi: 10.1002/ijgo.13102.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (1): 7–30. doi: 10.3322/caac.21590.

4. Richtarova A, Boudova B, Dundr P et al. Uterine smooth muscle tumors with uncertain malignant potential: analysis following fertility-saving procedures. Int J Gynecol Cancer 2023; 33 (5): 701–706. doi: 10.1136/ijgc-2022-004038.

5. Gronchi A, Miah AB, Dei Tos AP et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32 (11): 1348–1365. doi: 10.1016/j.annonc.2021.07.006.

6. Bonneau C, Thomassin-Naggara I, Dechoux S et al. Value of ultrasonography and magnetic resonance imaging for the characterization of uterine mesenchymal tumors. Acta Obstet Gynecol Scand 2014; 93 (3): 261–268. doi: 10.1111/aogs.12325.

7. Van den Bosch T, Dueholm M, Leone FP et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol 2015; 46 (3): 284–298. doi: 10.1002/uog.14806.

8. Ludovisi M, Moro F, Pasciuto T et al. Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. Ultrasound Obstet Gynecol 2019; 54 (5): 676–687. doi: 10.1002/uog.20270.

9. Cotrino I, Carosso A, Macchi C et al. Ultrasound and clinical characteristics of uterine smooth muscle tumors of uncertain malignant potential (STUMPs). Eur J Obstet Gynecol Reprod Biol 2020; 251 : 167–172. doi: 10.1016/j.ejogrb.2020.05.040.

10. Suzuki Y, Wada S, Nakajima A et al. Magnetic resonance imaging grading system for preoperative diagnosis of leiomyomas and uterine smooth muscle tumors. J Minim Invasive Gynecol 2018; 25 (3): 507–513. doi: 10.1016/j.jmig.2017.08.660.

11. Frühauf F, Burgetová A, Lambert L et al. Preoperative discrimination between uterine myomas and sarcomas. Ceska Gynekol 2024; 89 (4): 319–328. doi: 10.48095/cccg2024319.

12. Kubik-Huch RA, Weston M, Nougaret S et al. European Society of Urogenital Radiology (ESUR) guidelines: MR imaging of leiomyomas. Eur Radiol 2018; 28 (8): 3125–3137. doi: 10.1007/s00330-017-5157-5.

13. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18 (6): 535–558.

14. Wang L, Li S, Zhang Z et al. Prevalence and occult rates of uterine leiomyosarcoma. Medicine (Baltimore) 2020; 99 (33): e21766. doi: 10.1097/MD.0000000000021766.

15. Raspagliesi F, Maltese G, Bogani G et al. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. Gynecol Oncol 2017; 144 (1): 90–95. doi: 10.1016/j.ygyno.2016.11.002.

16. Bretthauer M, Goderstad JM, Løberg M et al. Uterine morcellation and survival in uterine sarcomas. Eur J Cancer 2018; 101 : 62–68. doi: 10.1016/j.ejca.2018.06.007.

17. Halaska MJ, Haidopoulos D, Guyon F et al. European Society of Gynecological Oncology statement on fibroid and uterine morcellation. Int J Gynecol Cancer 2017; 27 (1): 189–192. doi: 10.1097/IGC.0000000000000911.

18. Sagae S, Yamashita K, Ishioka S et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67 (1): 33–39. doi: 10.1159/000080283.

19. Mascilini F, Quagliozzi L, Moro F et al. Role of transvaginal ultrasound-guided biopsy in gynecology. Int J Gynecol Cancer 2020; 30 (1): 128–132. doi: 10.1136/ijgc-2019-000734.

20. Verschuere H, Froyman W, Van den Bosch T et al. Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses. Gynecol Oncol 2021; 161 (3): 845–851. doi: 10.1016/j.ygyno.2021.03.026.

21. Fischerova D, Cibula D, Dundr P et al. Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. Int J Gynecol Cancer 2008; 18 (4): 833–837. doi: 10.1111/j.1525-1438.2007.01015.x.

22. Woodcock NP, Glaves I, Morgan DR et al. Ultrasound-guided tru-cut biopsy of the breast. Ann R Coll Surg Engl 1998; 80 (4): 253–256.

23. Chopra S, Rowe EW, Laniado M et al. A prospective study analysing the effect of pain on probe insertion, and the biopsy strategy, on the patients’ perception of pain during TRUS-guided biopsy of the prostate. N Z Med J 2008; 121 (1287): 39–34.

24. Buonomo F, Bussolaro S, de Almeida Fiorillo C et al. Ultrasound-guided tru-cut biopsy in gynecological and non-gynecological pelvic masses: a single-center experience. J Clin Med 2022; 11 (9): 2534. doi: 10.3390/jcm11092534.

25. Epstein E, Van Calster B, Timmerman D et al. Subjective ultrasound assessment, the ADNEX model and ultrasound-guided tru-cut biopsy to differentiate disseminated primary ovarian cancer from metastatic non-ovarian cancer. Ultrasound Obstet Gynecol 2016; 47 (1): 110–116. doi: 10.1002/uog.14892.

26. Asp M, Mockute I, Måsbäck A et al. Tru-cut biopsy in gynecological cancer: adequacy, accuracy, safety and clinical applicability. J Multidiscip Healthc 2023; 16 : 1367–1377. doi: 10.2147/JMDH.S396788.

27. Zikan M, Fischerova D, Pinkavova I et al. Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound Obstet Gynecol 2010; 36 (6): 767–772. doi: 10.1002/uog.8803.

28. Mesenchymal tumours. In WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC Press 2020.

29. Mittal K, Joutovsky A. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol 2007; 104 (2): 362Y365. doi: 10.1016/j.ygyno.2006.08.034.

30. Kawamura N, Ichimura T, Takahashi K et al. Transcervical needle biopsy of uterine myoma-like tumors using an automatic biopsy gun. Fertil Steril 2002; 77 (5): 1060–1064. doi: 10.1016/s0015-0282 (02) 03064-9.

31. Tamura R, Kashima K, Asatani M et al. Preoperative ultrasound-guided needle biopsy of 63 uterine tumors having high signal intensity upon T2-weighted magnetic resonance imaging. Int J Gynecol Cancer 2014; 24 (6): 1042–1047. doi: 10.1097/IGC.0000000000000189.

32. Smadja J, El Zein S, Pierron G et al. Percutaneous uterine needle biopsy with microscopic and array-CGH analyses for preoperative sarcoma diagnosis in patients with suspicious myometrial tumors on MRI: a prospective pilot study (SARCGYN). Ann Surg Oncol 2023; 30 (2): 943–953. doi: 10.1245/s10434-022 -⁠ 12697-5.

33. Stukan M, Rutkowski P, Smadja J et al. Ultrasound-guided trans-uterine cavity core needle biopsy of uterine myometrial tumors to differentiate sarcoma from a benign lesion –⁠ description of the method and review of the literature. Diagnostics (Basel) 2022; 12 (6): 1348. doi: 10.3390/diagnostics12061348.